Feature Immunovaccine targets three clinical milestones By Len Zehr Immunovaccine (OTCQX:IMMVF; TSX:IMV) expects to report three clinical milestones for its killer T cell activation vaccine platform, DepoVax, in ovarian and HPV cancers in the next 12 months. “Our DepoVax... October 18, 2016